DMA Diamedica Therapeutics

DiaMedica Inc. (TSX VENTURE:DMA), a clinical stage biopharmaceutical company
developing novel treatments for various stages of type 2 diabetes, is pleased to
announce that Dr. Wayne Lautt, co-founder of DiaMedica, will be speaking today
at the International Union of Physiological Sciences 36th World Congress, a
prestigious meeting held every four years, in Kyoto Japan.


Dr. Lautt's presentation, entitled "Meal-induced insulin sensitization: role in
the pathophysiology and prevention of diabetes" will describe a nerve-signal
mechanism that DiaMedica believes is a fundamental cause of type 2 diabetes.


"This presentation affords the opportunity to describe a mechanism that the
Company believes is strongly connected to insulin resistance, the precursor to
type 2 diabetes, and to present data that DiaMedica's approach fully reverses
insulin resistance in a diabetic animal model" stated Dr. Lautt. "Furthermore,
data will be presented demonstrating that restoring this mechanism
re-establishes the ability of the body to store more nutrient energy in muscles,
where it can be burned off, rather than stored as fat, which leads to obesity."


About IUPS

The International Union of Physiological Sciences (IUPS) is an organization
which brings together physiologists from across the globe. The unifying
objective is to increase mankind's understanding of the functions of cells,
tissues, organs and organ systems. It is an adhering member of the Council for
International Organizations of Medical Sciences and participates in the work of
several Scientific Committees of the International Council for Science. The IUPS
publishes a journal, Physiology in cooperation with the American Physiological
Society. The articles are up-to-date reviews of modern physiology in order to
maintain a current knowledge of all fields of physiology.


About DiaMedica

DiaMedica is developing novel treatments for type 2 diabetes based on a 'nerve
signal' mechanism for which the Company has been issued two U.S. patents.
DiaMedica completed a successful phase II trial with its lead product, DM-71,
which demonstrated the ability to reduce HbA1c (blood sugar) levels and weight
in humans. DiaMedica also completed a successful phase II trial with its second
compound, DM-83, designed to measure changes in insulin and / or glucose. The
success of this clinical trial was highly significant as DiaMedica believes it
validated the novel 'nerve signal' mechanism that would designate the Company's
drugs as first-in-class.


The Company's third drug in development, DM-99, recently completed a phase II
clinical trial. Patients receiving DM-99 in Period 1 of this cross-over study
showed a decrease in baseline adjusted peak blood glucose concentration of 19%
(p equals 0.077) versus those receiving placebo as well as a decrease in
incremental glucose Area Under the Curve (AUC) 0-240 minutes of 31% (p equals
0.030) versus those receiving placebo. DM-199, a recombinant version of DM-99,
has been created with the expectation that it will a long-acting version of
DM-99. DiaMedica was recently awarded a contribution of up to $492,000 from the
National Research Council of Canada Industrial Research Assistance Program
(NRC-IRAP) to fund the development of DM-199. DiaMedica has been recognized as
one of the Top Ten(TM) Life Science companies in Canada for the past two years
by the Ottawa Centre for Research and Innovation.


Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking
information within the meaning of applicable Canadian provincial securities
legislation (collectively, "forward-looking statements"). These forward-looking
statements relate to, among other things, our objectives, goals, targets,
strategies, intentions, plans, beliefs, estimates and outlook, including,
without limitation, our anticipated future operating results, and can, in some
cases, be identified by the use of words such as "believe," "anticipate,"
"expect," "intend," "plan," "will," "may" and other similar expressions. In
addition, any statements that refer to expectations, projections or other
characterizations of future events or circumstances are forward-looking
statements.


These statements reflect management's current beliefs and are based on
information currently available to management. Certain material factors or
assumptions are applied in making forward-looking statements, and actual results
may differ materially from those expressed or implied in such statements.
Important factors that could cause actual results to differ materially from
these expectations include, among other things: DiaMedica's early stage of
development, lack of product revenues and history of operating losses,
uncertainties related to clinical trials and product development, rapid
technological change, uncertainties related to forecasts, competition, potential
product liability, additional financing requirements and access to capital,
unproven markets, supply of raw materials, income tax matters, management of
growth, partnerships for development and commercialization of technology,
effects of insurers' willingness to pay for products, system failures,
dependence on key personnel, foreign currency risk, risks related to regulatory
matters and risks related to intellectual property and other risks detailed from
time to time in DiaMedica's filings with Canadian securities regulatory
authorities, as well as DiaMedica's ability to anticipate and manage the risks
associated with the foregoing. Additional information about these factors and
about the material factors or assumptions underlying such forward-looking
statements may be found in the body of this news release, as well as under the
heading "Risk Factors" contained in DiaMedica's final long-form prospectus dated
March 12, 2007. DiaMedica cautions that the foregoing list of important factors
that may affect future results is not exhaustive. When relying on DiaMedica's
forward-looking statements to make decisions with respect to DiaMedica,
investors and others should carefully consider the foregoing factors and other
uncertainties and potential events.


These risks and uncertainties should be considered carefully and prospective
investors should not place undue reliance on the forward-looking statements.
Although the forward-looking statements contained in this press release are
based upon what management believes to be reasonable assumptions, DiaMedica
cannot provide assurance that actual results will be consistent with these
forward-looking statements. DiaMedica undertakes no obligation to update or
revise any forward-looking statement.

DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jun 2024 to Jul 2024

DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jul 2023 to Jul 2024